Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 6;2(3):475-477.
doi: 10.1002/jha2.239. eCollection 2021 Aug.

COVID-19-associated pseudothrombocytopenia

Ruben Van Dijck  1 , Mandy N Lauw  1 , Maurice Swinkels  1 , Henk Russcher  2 , A J Gerard Jansen  1
Affiliations

COVID-19-associated pseudothrombocytopenia

Ruben Van Dijck et al. EJHaem. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Platelet counts in EDTA and citrate anticoagulated blood in our COVID‐19 infected patient with pseudothrombocytopenia. (*) Onset of respiratory symptoms. (**) Start of hospitalization and positive SARS‐CoV‐2 PCR test. (***) Discharge from hospital. (****) Positive SARS‐CoV‐2 IgM and total antibody ELISA (CE‐IVD) indicating SARS‐CoV‐2 seroconversion. Starting from the moment of hospitalization, our patient received treatment with ceftriaxone and ciprofloxacin for 5 consecutive days, dexamethasone for 10 consecutive days and prophylactic nadroparin until discharge
FIGURE 2
FIGURE 2
Peripheral blood smear showing platelet agglutination in EDTA in our COVID‐19 infected patient with pseudothrombocytopenia. (A) Picture made with CellaVision (DM96) microscope. Original magnification ×100 for each panel. All inserts refer to the same blood sample. This blood smear was performed on the day of the nadir platelet count, which was 10 days after diagnosis of COVID‐19 infection, and very convincingly shows platelet agglutination in EDTA anticoagulated blood, indicating pseudothrombocytopenia. (B) Picture made with CellaVision (DM96) microscope. Original magnification ×100. Detail of the same blood smear showing platelet agglutination in EDTA anticoagulated blood
See this image and copyright information in PMC

References

    1. Liu Y, Sun W, Guo Y, Jin J, Huang M, Yu Z, et al. Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study. Platelets. 2020;209:1–7. - PMC - PubMed
    1. Rampotas A, Pavord S. Platelet aggregates, a marker of severe COVID‐19 disease. J Clin Pathol. 2020. 10.1136/jclinpath-2020-206933 - DOI - PubMed
    1. Guan WJ, Ni ZY, Hu Y, Liang W‐H, Ou C‐Q, He J‐X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20. - PMC - PubMed
    1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13. - PMC - PubMed
    1. Larsen JB, Pasalic L, Hvas AM. Platelets in coronavirus disease 2019. Semin Thromb Hemost. 2020;46:823–5. - PMC - PubMed